Ofosu Andrew, Ramai Daryl, Morgan Amanda, Chan Christina, Adler Douglas G, Siddiqui Ali
Division of Gastroenterology, University of Cincinnati, Cincinnati, OH, USA.
Division of Gastroenterology and Hepatology, University of Utah Health, Salt Lake City, UT, USA.
Endosc Ultrasound. 2024 Jan-Feb;13(1):1-5. doi: 10.1097/eus.0000000000000036. Epub 2024 Feb 1.
Recent years have brought to light newly developed therapeutic modalities for the treatment of premalignant and malignant pancreatic lesions. The role of EUS-guided radiofrequency ablation (EUS-RFA) as a treatment modality for malignant pancreatic lesions is still under evaluation. Several animal studies and human studies have demonstrated the safety and efficacy of EUS-RFA in the management of premalignant and malignant pancreatic lesions. EUS-RFA therapy can potentially ablate these lesions safely and with minimally invasive techniques. In this article, we provide an updated review of the application of EUS-RFA of pancreatic lesions. We also review the clinical efficacy and safety of this technique and future directions.
近年来，已出现了用于治疗胰腺癌前病变和恶性病变的新开发治疗方法。超声内镜引导下射频消融术（EUS-RFA）作为一种治疗胰腺恶性病变的方法，其作用仍在评估中。多项动物研究和人体研究已证明EUS-RFA在治疗胰腺癌前病变和恶性病变方面的安全性和有效性。EUS-RFA治疗有可能通过微创技术安全地消融这些病变。在本文中，我们对胰腺病变的EUS-RFA应用进行了最新综述。我们还回顾了该技术的临床疗效、安全性及未来发展方向。
